Pipeline
← Отчётные звонки
01
02
03
04 05 06
Тон
Капзатраты
A1 A2 A3 A4 A5
REGN
FY2025 Q4
Улучшается
Отчётный звонок Regeneron Pharmaceuticals, Inc.
Вывод Buzzberg
Regeneron anticipates at least four FDA approvals in 2026, including three new molecular entities.
Regeneron's Q4 2025 call showcased continued strength in Dupixent sales and a clear strategy to defend against Eylea biosimilars by converting to the high-dose Eylea-HD. Management struck an optimistic tone on the pipeline, with multiple high-value readouts expected in oncology and immunology in 2026. The call also surfaced a potential 'Trojan horse' obesity drug concept combining a GLP-1 class medicine with a PCSK9 inhibitor. Dupixent global sales grew 32% YoY to $4.9B, with strong momentum in launches like COPD and chronic spontaneous urticaria.
Вывод Buzzberg Regeneron anticipates at least four FDA approvals in 2026, including three new molecular entities. Regeneron's Q4 2025 call showcased continued strength in Dupixent sales and a clear strategy to defend against Eylea biosimilars by converting to the high-dose Eylea-HD. Management struck an optimistic tone on the pipeline, with multiple high-value readouts expected in oncology and immunology in 2026. The call also surfaced a potential 'Trojan horse' obesity drug concept combining a GLP-1 class medicine with a PCSK9 inhibitor. Dupixent global sales grew 32% YoY to $4.9B, with strong momentum in launches like COPD and chronic spontaneous urticaria. Читать полный анализСвернуть анализ
Regeneron's Q4 2025 call showcased continued strength in Dupixent sales and a clear strategy to defend against Eylea biosimilars by converting to the high-dose Eylea-HD. Management struck an optimistic tone on the pipeline, with multiple high-value readouts expected in oncology and immunology in 2026. The call also surfaced a potential 'Trojan horse' obesity drug concept combining a GLP-1 class medicine with a PCSK9 inhibitor. Dupixent global sales grew 32% YoY to $4.9B, with strong momentum in launches like COPD and chronic spontaneous urticaria.
- Eylea franchise: Eylea-HD is growing but Eylea 2mg faces inevitable decline against upcoming biosimilars; the PFS approval is the next catalyst for Eylea-HD.
- Linezolic is a major near-term pipeline focus, showing high complete response rates in myeloma and amyloidosis; multiple pivotal studies are underway.
- Management is emphasizing its 'Trojan horse' approach to obesity, combining a GLP-GIP agonist with its PCSK9 antibody for dual weight loss and cholesterol reduction.
Выручка$3.8843BФакт
EPS$11.44Факт
Валовая маржа84.95%Факт
Операционная маржа22.65%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Clinical Data
First-line metastatic melanoma LAG3 combo readout expected in first half.
Commercial
Liptio adjuvant CSCC launch is off to a great start.
Показать ещё 3 тезиса
Regulatory
Eylea HD pre-filled syringe decision expected in late April.
Collaboration
Sanofi collaboration development balance expected fully reimbursed by mid-2026.
Guidance
2026 R&D spend guided to $5.9-6.1 billion, up from 2025.
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $3.8843B | Факт |
| EPS | $11.44 | Факт |
| Валовая маржа | 84.95% | Факт |
| Операционная маржа | 22.65% | Факт |
| Свободный денежный поток | $0.922B | Факт |
| Капзатраты | $0.2487B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Капзатраты | FY2026 | $1.1B–$1.3B | $1.2B | Обозначен |
| Валовая маржа | FY2026 | 83%–84% | 83.5% | Обозначен |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management expressed confidence in pipeline breadth, upcoming data readouts, and differentiated product profiles, while acknowledging competitive pressures in certain areas.
Инвестиции и мощности
Management expects 2026 capital expenditures to be in the range of $1.1 to $1.3 billion, primarily related to expanding R&D facilities at Tarrytown headquarters and investments in manufacturing network to support the growing commercial portfolio and pipeline.
все упомянутые компании ниже: 6
Компаниис момента звонка
Партнёры
Партнёры
Chris Fethmore
Bayer collaboration on Eylea products remains a substantial source of international revenue and profit.
Доказательства
“Total buyer collaboration revenue was $319 million, of which $270 million related to our share of net profits outside the United States.”
Партнёры
Chris Fethmore
Novartis's high sales of Ilaris triggered the highest royalty tier, boosting Regeneron's other revenue.
Доказательства
“Alaris net sales exceeded $1.5 billion in 2025, achieving the top royalty tier of 15% for the first time.”
Партнёры
Chris Fethmore
Sanofi's Dupixent royalty recharge is on track to be fully reimbursed by mid-2026, after which the collaboration economics switch to full profit share. — This is a major profitability inflection point for Regeneron, as its profit share will increase materially in the second half of 2026.
Доказательства
“Dupixent's continued strength enabled a rapid reimbursement of the development balance in 2025, which we now expect to be fully reimbursed by mid-2026.”
Конкуренты
Конкуренты
Dr. George Yancopoulos
Management highlights a competitor's failure to underscore the uniqueness of Regeneron's antibody discovery technology.
Доказательства
“For example, Amgen, using an inferior humanized mouse approach, tried to make a Dupixent that is starting the same receptor as we did, and their antibody completely failed in all their clinical trials.”
Конкуренты
Marion McCourt
Libtayo is gaining market share in first-line non-small cell lung cancer against competing PD-1 immunotherapies.
Доказательства
“new patient market share in this setting greater than Optivo, Tecentric, and Infinsi combined.”
Внешние сигналы
Альфа цепочки поставок · 5с момента звонка
Eylea-HD and Eylea wholesaler inventory levels were elevated by ~$30M at end of Q4 2025, expected to negatively impact Q1 2026 net sales.
Доказательства
“wholesaler inventory levels were elevated by approximately 30 million at the end of the fourth quarter for ILEA HD as well as ILEA. We expect first quarter net sales will be negatively impacted as the inventory is absorbed.”
Eylea-HD is now nearly half of total Eylea franchise sales and is growing, but Eylea 2mg is expected to face intense competitive pressure in H2 2026 with biosimilar launches.
Доказательства
“While we anticipate continued growth in ILEA-HD this year, ILEA 2 mg will continue to be under competitive pressure, which is expected to intensify the second half of 2026 as multiple biosimilar products are launched in the United States.”
There is a potential 'Trojan horse' strategy for obesity: a co-formulation of a GLP-GIP with PCSK9 inhibitor to address both weight loss and cholesterol, potentially expanding the market by targeting a broader population.
Sanofi's Dupixent royalty recharge is on track to be fully reimbursed by mid-2026, after which the collaboration economics switch to full profit share.
The company is expanding into 'next-generation' therapies, aiming to improve upon its existing blockbusters like Dupixent by leveraging its genetics-based antibody discovery and formulation capabilities.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 6. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.